Zelira Therapeutics (OTCMKTS:ZLDAF) Trading 13.9% Higher – Should You Buy?

by · The Markets Daily

Shares of Zelira Therapeutics Limited (OTCMKTS:ZLDAF – Get Free Report) shot up 13.9% on Monday . The stock traded as high as $0.2660 and last traded at $0.2660. 171 shares were traded during trading, a decline of 82% from the average session volume of 973 shares. The stock had previously closed at $0.2335.

Zelira Therapeutics Price Performance

The stock has a 50 day simple moving average of $0.22 and a 200 day simple moving average of $0.25.

About Zelira Therapeutics

(Get Free Report)

Zelira Therapeutics Ltd is a clinical-stage biotechnology company focused on the development and commercialization of proprietary cannabinoid-based therapies. The company leverages a portfolio of clinical and preclinical drug candidates designed to address unmet medical needs in areas such as chronic pain, autism spectrum disorder, Alzheimer’s disease and sleep disorders. Utilizing patented formulation and delivery platforms, Zelira aims to optimize efficacy and safety profiles of plant-derived cannabinoids.

The company pursues a dual geography strategy through its Australian and North American operations.

Recommended Stories